SEC Comment Letter for Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281) (ELDN) — Mar 31, 2020
Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281)
Date: March 31, 2020 · CIK: 0001404281 · Accession: 0000000000-20-002791
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237379
Letter
March 31, 2020 Gregory J. Flesher Chief Executive Officer Novus Therapeutics, Inc. 19900 MacArthur Blvd., Suite 550 Irvine, CA 92612 Re:Novus Therapeutics, Inc. Registration Statement on Form S-1 Filed March 25, 2020 File No. 333-237379 Dear Mr. Flesher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan A. Murr, Esq.
Show Raw Text
March 31, 2020
Gregory J. Flesher
Chief Executive Officer
Novus Therapeutics, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, CA 92612
Re:Novus Therapeutics, Inc.
Registration Statement on Form S-1
Filed March 25, 2020
File No. 333-237379
Dear Mr. Flesher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ryan A. Murr, Esq.